Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-D2
2025-522029-37-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of surovatamig in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence and severity of AEs, SAEs, AESIs, and events of clinical interest (Safety run-in), AEs leading to discontinuation or dose modification of AZD0486 (Safety run-in) and 2 more. Planned start Jan 2026; status: authorised.
02
Drugs
surovatamig
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2025-522029-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522029-37-00.